Literature DB >> 6878101

Alpha 2HS-glycoprotein in the serum and urine of patients with renal diseases.

B K Kishore, F Gejyo, M Arakawa.   

Abstract

The concentration of alpha 2HS-glycoprotein (alpha 2HS-GP), as measured by the single radial immunodiffusion technique in the sera of 52 patients with various renal diseases and varying degrees of proteinuria, was found to be significantly reduced (P less than 0.001) when compared to the control values. Out of the 52 patients examined, 34 were found to excrete alpha 2HS-GP in urine with no correlation between the serum and urine levels of this protein. Although there is a statistically significant correlation between the clearances of albumin and alpha 2HS-GP, in only six patients were the clearances of alpha 2HS-GP within +/- 25% of albumin clearance. Twelve had higher, and 16 had lower, relative clearances of alpha 2HS-GP. The relative clearance of alpha 2HS-GP had no relation to the serum levels of alpha 2HS-GP, but correlated with the degree of proteinuria and the type of histological lesion in the kidney. In conclusion, there is a quantitative reduction of serum alpha 2HS-GP in patients with renal diseases. It appears that the degree of proteinuria and the type of renal lesion influences its selective handling by the kidneys.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6878101      PMCID: PMC2417412          DOI: 10.1136/pgmj.59.691.304

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  8 in total

1.  Detection of fibrinogen degradation products by use of antibody coated latex particles. The possibilities and limits of the method.

Authors:  E J Melliger
Journal:  Thromb Diath Haemorrh       Date:  1970-05-31

2.  Renal clearance of 15 plasma proteins in renal disease.

Authors:  J Bienenstock; J Poortmans
Journal:  J Lab Clin Med       Date:  1970-02

3.  Purification and characterization of the two forms of human plasma alpha 2HS-glycoprotein.

Authors:  F Gejyo; K Schmid
Journal:  Biochim Biophys Acta       Date:  1981-11-30

4.  alpha 2HS-glycoprotein serum levels in protein-energy malnutrition.

Authors:  F P Schelp; O Thanangkul; V Supawan; P Pongpaew
Journal:  Br J Nutr       Date:  1980-03       Impact factor: 3.718

5.  Opsonic properties of human serum alpha-2 hs glycoprotein.

Authors:  C J van Oss; C F Gillman; P M Bronson; J R Border
Journal:  Immunol Commun       Date:  1974

6.  Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant.

Authors:  J P Lebreton; F Joisel; J P Raoult; B Lannuzel; J P Rogez; G Humbert
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

7.  Plasma proteins present in human cortical bone: enrichment of the alpha2HS-glycoprotein.

Authors:  J T Triffitt
Journal:  Calcif Tissue Res       Date:  1976-11-24

8.  Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity.

Authors:  A M Baskies; P B Chretien; J F Weiss; R W Makuch; R A Beveridge; W J Catalona; H E Spiegel
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

  8 in total
  4 in total

Review 1.  Pathogenesis of vascular calcification in dialysis patients.

Authors:  Markus Ketteler; Ralf Westenfeld; Georg Schlieper; Vincent Brandenburg
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

2.  Serum alpha 2-HS glycoprotein concentration in patients with hematological malignancies. A follow-up study.

Authors:  L Kalabay; K Cseh; S Benedek; S Fekete; T Masszi; K Herjeczki; T Pozsonyi; L Jakab; L Jakab
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

3.  Noncollagenous proteins in normal and pathological human bone.

Authors:  K J Quelch; W G Cole; R A Melick
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

4.  What does the circulating AHSG/fetuin-A level tell us?

Authors:  Junichiro James Kazama
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.